Bristol Myers Squibb - aktuální graf a vývoj ceny
Bristol-Myers Squibb: Still Too Many Uncertainties In The I/O Space
Bristol-Myers Squibb: Still Too Many Uncertainties In The I/O Space Seeking Alpha - Jun 14, 2017 In spite of the share price falling more than 30% since mid-2016 after disappointing results for Opdivo in lung cancer in the Checkmate-026 study, I don't think Bristol-Myers Squibb (NYSE:BMY) offers a compelling risk/reward with the stock trading at ... Bristol-Myers Squibb (BMY) to Present Research on RA Patients With Highly ... - StreetInsider.com Bristol-Myers Squibb Co (BMY) Put-Call Ratio Skews Positive - StockNews.com (blog)14. 06. 2017
Bristol-Myers Squibb Is Poised for a Breakout
Bristol-Myers Squibb Is Poised for a Breakout TheStreet.com - Jun 19, 2017 Bristol-Myers Squibb Co. (BMY) has been held in check by a very heavy 200 day moving average for nearly all of 2017. The stock managed to close above this key level on Monday for the first time since early August 2016. Estimating the intrinsic value of Bristol-Myers Squibb Company (BMY) - Simply Wall St Bristol-Myers Squibb Company (BMY) Is Now On The Radar Because Of Its ... - NY Stock News19. 06. 2017
Bristol-Myers Squibb reports data from phase 1/2 trial for cancers associated ...
Bristol-Myers Squibb reports data from phase 1/2 trial for cancers associated ... MarketWatch - Jun 2, 2017 Bristol-Myers Squibb Co. BMY, +2.25% reported results from a phase 1/2 clinical trial looking at the company's blockbuster cancer drug Opdivo in patients with human papillomavirus (HPV)-associated cancers premarket Friday. Bristol-Myers Squibb Breaks Above 200-Day Moving Average - Bullish for BMY - Nasdaq Latest figures makes these Stock Even More Attractive: Bristol-Myers Squibb ... - StockNewsJournal02. 06. 2017